Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Long-Term Study of LY2140023 Compared to Standard of Care in Schizophrenia
NCT01129674Phase 3Terminated
- Sponsor
- Denovo Biopharma
- Start
- Jun 2010
- Primary completion
- Oct 2012
- Countries
- 9
01
Overview
A Phase 3 trial of pomaglumetad methionil in schizophrenia, sponsored by Denovo Biopharma. Started Jun 2010; status: terminated.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01129674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129674.